Listing should be done asap, if 1-2 investors are lined up and we meet IPO/Nasdaq requirements get it done. The current momentum will attract real investors while Covid interest is still "hot" . Each positive PR will ignite excitement and hopefully increase volume/pps. Don't forget it's a race to the finish line and 300+ potential vaccines/therapies competing for market share.

Here is a reminder of approx 200 potential players , some already well rewarded in pps/funding.

https://www.who.int/publications/m/item/draft...e-vaccines